An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT ID: NCT07033026
Last Updated: 2025-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
136 participants
INTERVENTIONAL
2025-06-30
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)
NCT05340231
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
NCT07314528
Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
NCT07152210
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
NCT07014254
Short Running Head Obesity in Rectal Cancer Patients
NCT04759638
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NGM120 Treatment Group A
NGM120 low dose given subcutaneously every 4 weeks
NGM120 Q4W
NGM120 given subcutaneously every 4 weeks
NGM120 Treatment Group B
Placebo low dose given subcutaneously every 4 weeks
Placebo given
Placebo given subcutaneously every 4 weeks
NGM120 Treatment Group C
NGM120 high dose given subcutaneously every 4 weeks
NGM120 Q4W
NGM120 given subcutaneously every 4 weeks
NGM120 Treatment Group D
NGM120 high dose given subcutaneously every 8 weeks
NGM120 Q8W
NGM120 given subcutaneously every 8 weeks
NGM120 Treatment Group E
Placebo high dose given subcutaneously every 4 weeks
Placebo given
Placebo given subcutaneously every 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGM120 Q4W
NGM120 given subcutaneously every 4 weeks
NGM120 Q8W
NGM120 given subcutaneously every 8 weeks
Placebo given
Placebo given subcutaneously every 4 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Cachexia defined by Fearon criteria of weight loss.
3. Signed informed consent.
Exclusion Criteria
2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
3. Have cachexia caused by other reasons.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NGM Biopharmaceuticals, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NGM Study Director
Role: STUDY_DIRECTOR
NGM Biopharmaceuticals, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NGM Clinical Study Site
Laredo, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
120-CX-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.